Literature DB >> 15705881

CDKN2A common variants and their association with melanoma risk: a population-based study.

Tadeusz Debniak1, Rodney J Scott, Tomasz Huzarski, Tomasz Byrski, Andrzej Rozmiarek, Bogusław Debniak, Elzbieta Załuga, Romuald Maleszka, Józef Kładny, Bohdan Górski, Cezary Cybulski, Jacek Gronwald, Grzegorz Kurzawski, Jan Lubinski.   

Abstract

The population frequencies of the CDKN2A variants remain undetermined. In Poland there are three common variants of CDKN2A: an alanine to threonine substitution (A148T), Nt500c>g and Nt540c>t, which have been detected in other populations. To establish if they are associated with an increased malignant melanoma (MM) risk we did an association study based on genotyping 471 patients with MM and 1,210 random control subjects from the same Polish population. We found a significantly increased frequency of the A148T variant among patients with MM (7.0%) in comparison with the general population (2.9%). The incidence of the A148T variant remained greater in both unselected and familial melanoma subgroups. A statistically significant positive association was seen for unselected MM (odds ratio, 2.529; P = 0.0003), especially in patients diagnosed under 50 years of age (odds ratio, 3.4; P = 0.0002). The A148T carrier population (heterozygous G/A alleles) was more likely to have a relative with malignancy compared with the noncarrier population (57% versus 36%, respectively; P = 0.03). Further examination of the CDKN2A promoter sequence done in 20 melanoma patients with the A148T change (heterozygous G/A alleles) and 20 patients with MM without this alteration identified it was in linkage disequilibrium with a polymorphism in the promoter region at position P-493. We found no statistically significant overrepresentation of the Nt500c>g and the Nt540c>t polymorphisms in the Polish melanoma population. In conclusion, the A148T variant of the CDKN2A gene seems to be associated with an increased risk of development of MM. Additional studies are required to confirm whether this particular change is associated with increased risk of other nonmelanoma malignancies.

Entities:  

Mesh:

Year:  2005        PMID: 15705881

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Authors:  Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova
Journal:  Pathol Oncol Res       Date:  2014-08-23       Impact factor: 3.201

2.  CDKN2A and MC1R variants found in Cypriot patients diagnosed with cutaneous melanoma.

Authors:  Georgia Koulermou; Christos Shammas; Andreas Vassiliou; Tassos C Kyriakides; Constantina Costi; Vassos Neocleous; Leonidas A Phylactou; Maria Pantelidou
Journal:  J Genet       Date:  2017-03       Impact factor: 1.166

3.  Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Rabe; Katrina S Pedersen; Yanhong Wu; Hugues Sicotte; Gloria M Petersen
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

4.  A common variant of CDKN2A (p16) predisposes to breast cancer.

Authors:  T Debniak; B Górski; T Huzarski; T Byrski; C Cybulski; A Mackiewicz; S Gozdecka-Grodecka; J Gronwald; E Kowalska; O Haus; E Grzybowska; M Stawicka; M Swiec; K Urbański; S Niepsuj; B Waśko; S Góźdź; P Wandzel; C Szczylik; D Surdyka; A Rozmiarek; O Zambrano; M Posmyk; S A Narod; J Lubinski
Journal:  J Med Genet       Date:  2005-05-06       Impact factor: 6.318

5.  Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression.

Authors:  Michael S Cunnington; Mauro Santibanez Koref; Bongani M Mayosi; John Burn; Bernard Keavney
Journal:  PLoS Genet       Date:  2010-04-08       Impact factor: 5.917

6.  Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients.

Authors:  Katarzyna Kiwerska; Małgorzata Rydzanicz; Andrzej Kram; Martyna Pastok; Agata Antkowiak; Wenancjusz Domagała; Krzysztof Szyfter
Journal:  Mol Biol Rep       Date:  2009-08-19       Impact factor: 2.316

7.  3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.

Authors:  David Tovar-Parra; Sebastián Ramiro Gil-Quiñones; John Nova; Luz D Gutiérrez-Castañeda
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

8.  Low-risk Genes and Multi-organ Cancer Risk in the Polish Population.

Authors:  Tadeusz Debniak; Cezary Cybulski; Grzegorz Kurzawski; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Janina Suchy; Bartłomiej Masojć; Marek Mierzejewski; Marcin Lener; Urszula Teodorczyk; Krzysztof Medrek; Elzbieta Złowocka; Ewa Grabowska-Kłujszo; Katarzyna Nej-Wołosiak; Anna Szymańska; Jolanta Szymańska-Pasternak; Joanna Matyjasik; Thierry van de Wetering; Anna Jakubowska; Oleg Oszurek; Aleksandra Tołoczko-Grabarek; Jennifer Castaneda; Rodney Scott; Steven A Narod; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2006-01-15       Impact factor: 2.857

9.  DNA testing for variants conferring low or moderate increase in the risk of cancer.

Authors:  Grzegorz Kurzawski; Janina Suchy; Cezary Cybulski; Joanna Matyjasik; Tadeusz Debniak; Bohdan Górski; Tomasz Huzarski; Anna Janicka; Jolanta Szymanska-Pasternak; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

10.  Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.

Authors:  Matthew F Buas; David M Levine; Karen W Makar; Heidi Utsugi; Lynn Onstad; Xiaohong Li; Patricia C Galipeau; Nicholas J Shaheen; Laura J Hardie; Yvonne Romero; Leslie Bernstein; Marilie D Gammon; Alan G Casson; Nigel C Bird; Harvey A Risch; Weimin Ye; Geoffrey Liu; Douglas A Corley; Patricia L Blount; Rebecca C Fitzgerald; David C Whiteman; Anna H Wu; Brian J Reid; Thomas L Vaughan
Journal:  Carcinogenesis       Date:  2014-10-03       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.